Navigation Links
U-M researchers advocate national strategic approach to therapeutic cancer vaccines

ANN ARBOR, Mich. Vaccines that save lives by preventing disease have been around for centuries. Now, new vaccines that treat cancer are being developed, but how they will be combined with existing treatments is not clear.

Researchers at the University of Michigan Health System recommend that a national strategy be developed for bringing therapeutic cancer vaccines to patient care, so that cancers with less effective treatment options are priority targets.

"Vaccines that prevent disease have profoundly changed the lives of billions of people around the world," says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. "A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options."

Davis and co-author Elias J. Dayoub, a student at the U-M Medical School, published a commentary in the June 8 theme issue on cancer of the Journal of the American Medical Association.

When germs such as viruses or bacteria enter the body, the human immune system recognizes those germs as something abnormal and attacks them. Preventive vaccines use this natural response to prime the body's immune system so it can respond to bacteria such as pertussis (the cause of whooping cough) or viruses such as polio and measles.

With cancer cells, however, it is hard for the immune system to detect the "invaders," since they are the human body's own cells gone bad. Therapeutic cancer vaccines can enable the immune system to recognize undetected harmful cells and generate a response to fight back.

Lung cancer, pancreatic cancer and types of leukemia's all have lower survival rates than many other cancers because they respond poorly to currently available chemotherapy, radiation and surgery.

More than 200,000 Americans died from these cancers in 2010more deaths than from breast, prostate and colon cancer combined. Davis suggests that therapeutic vaccines can be used to improve the survival rates of patients with leukemia, lung cancer and pancreatic cancer and also for less common tumors that have similarly poor survival rates.

In 2010, the first cancer therapeutic vaccine was approved for specific forms of prostate cancer. Davis calls it "a major milestone for the entire class of therapeutic cancer vaccines in the United States."

Current research suggests it may be easier for scientists to develop specific vaccines, but Davis emphasizes that what is scientifically easiest may not necessarily benefit the broadest and largest groups of patients.

"While pharmaceutical research and development clearly can lead to exciting advances in care, it may take a strategic plan to help channel creative energy and effort into certain products that maximize benefit for the greatest number of patients over the shortest time frame," says Davis.

A strategic plan could include targeted funding for research and clinical trials that test specific vaccine candidates, explains Davis.

With currently available treatments, two out of every three people in the United States who are diagnosed with cancer survive for at least five years, according to the National Cancer Institute. Complications from these treatments can reduce patients' quality of life, though. Vaccines may potentially offer fewer side effects.

"While it is too early to claim success for therapeutic cancer vaccines, they offer patients and families facing cancer a new ray of hope," concludes Davis.


Contact: Imran Hyder
University of Michigan Health System

Related medicine news :

1. Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. Calorie-burning brown fat is a potential obesity treatment, researchers say
5. City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO
6. U of Alberta researchers hoping to stop heart disease in cancer patients before it starts
7. U of A researchers hope to stop heart
8. UofL researchers uncover mechanism in saliva production
9. UF researchers suggest cholera vaccination strategies for Zimbabwe
10. Researchers characterize epigenetic fingerprint of 1,628 people
11. Researchers develop strategy to improve patient adherence
Post Your Comments:
(Date:11/25/2015)... San Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... $15,000 in prizes were awarded to winners of the Create Real Impact awards. ... and creative expression to help stem the tide of distracted and reckless driving, the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a ... services to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus ... amount of time the doctor uses other traditional cutting tools, such as the scalpel ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... ... are national leaders when it comes to several aspects of orthopedic care. They ... joint replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ ... "Company") (NYSE: MR ), a ... medical devices worldwide, today announced that ... general meeting of shareholders at the ... Grand Century, 193 Prince Edward West Road, ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... heute bekanntgegeben, dass sie eine Lizenz für das Patent ... Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma ... von FUI AAP8 ins Leben gerufenen und von Edelris ... wurde FXR als ein Behandlungsziel für HBV identifiziert, und ...
Breaking Medicine Technology: